BRIEF-Celldex Therapeutics opens enrollment in phase 1/2 study of CDX-014
July 11, 2016 at 16:53 PM EDT
* Enrollment has opened in phase 1/2 study of CDX-014 in advanced renal cell carcinoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)